{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:05:38Z","timestamp":1783062338095,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.01.020","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T05:01:55Z","timestamp":1488776515000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials"],"prefix":"10.1016","volume":"76","author":[{"given":"Angela","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline O.","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Michalarea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Rallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Rhoda","family":"Molife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana N.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.01.020_bib1","series-title":"Ovarian cancer incidence and mortality","author":"UK CR","year":"2015"},{"key":"10.1016\/j.ejca.2017.01.020_bib2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib3","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib4","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib5","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","article-title":"Experience with bevacizumab in the management of epithelial ovarian cancer","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-10-2144","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumours","volume":"17","author":"Diamond","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/1471-2407-11-453","article-title":"The PACOVAR-trial: a phase I\/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer","volume":"11","author":"Eichbaum","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2017.01.020_bib8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/bjc.2013.126","article-title":"New perspectives on molecular targeted therapy in ovarian clear cell carcinoma","volume":"108","author":"Tan","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.020_bib9","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.01.020_bib11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/5042","article-title":"PIK3CA is implicated as an oncogene in ovarian cancer","volume":"21","author":"Shayesteh","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2017.01.020_bib12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumours","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.01.020_bib13","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1200\/JCO.2003.11.052","article-title":"Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"21","author":"Havrilesky","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.01.020_bib15","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.humpath.2006.10.007","article-title":"Alternate molecular genetic pathways in ovarian carcinomas of common histological types","volume":"38","author":"Willner","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2017.01.020_bib17","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.01.020_bib18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0090-8258(03)00264-6","article-title":"Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma","volume":"90","author":"Gemignani","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","article-title":"Early events in the pathogenesis of epithelial ovarian cancer","volume":"26","author":"Landen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","article-title":"Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumours with dasatinib","volume":"15","author":"Miller","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2017.01.020_bib21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2017.01.020_bib22","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.01.020_bib23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2017.01.020_bib25","doi-asserted-by":"crossref","first-page":"35132","DOI":"10.18632\/oncotarget.9048","article-title":"Continuous anti-angiogenic therapy after tumour progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience","volume":"7","author":"Hou","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejca.2017.01.020_bib26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib28","series-title":"TESARO's niraparib significantly improved progression-free survival for patients with ovarian cancer in both cohorts of the phase 3 NOVA trial","author":"Bio","year":"2016"},{"key":"10.1016\/j.ejca.2017.01.020_bib29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib31","doi-asserted-by":"publisher","first-page":"861401","DOI":"10.1155\/2011\/861401","article-title":"Perceptions and referral trends into phase I oncology trials: results of a clinical survey","volume":"2011","author":"Brunetto","year":"2011","journal-title":"J Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib32","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib33","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-11-2217","article-title":"Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience","volume":"18","author":"Wheler","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib34","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","article-title":"Cancer therapy directed by comprehensive genomic profiling: a single center study","volume":"76","author":"Wheler","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib35","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.01.020_bib36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.020_bib37","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T05:42:28Z","timestamp":1568871748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917300813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":37,"alternative-id":["S0959804917300813"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}